Recent Research Analysts’ Ratings Changes for Veracyte (VCYT)

Several analysts have recently updated their ratings and price targets for Veracyte (NASDAQ: VCYT):

• 11/9/2026 – Veracyte had its price target lowered by UBS Group from $65.00 to $35.00. They now have a “buy” rating on the stock.
• 11/7/2026 – Veracyte was downgraded by Wall Street Zen from “buy” to “hold”.
• 11/6/2026 – Veracyte was downgraded by Wolfe Research from “strong-buy” to “hold”.
• 11/5/2026 – Veracyte had its price target lowered by Needham & Company LLC from $69.00 to $46.00. They now have a “buy” rating on the stock.
• 11/5/2026 – Veracyte was downgraded by Leerink Partners from “outperform” to “market perform”. They now have a $35.00 price target on the stock, down from $55.00.
• 10/10/2026 – Veracyte was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 10/2/2026 – Veracyte was downgraded by Zacks Research from “strong-buy” to “hold”.
• 9/24/2026 – Veracyte was downgraded by Weiss Ratings from “hold (c+)” to “hold (c)”.
• 9/15/2026 – Veracyte had its “buy” rating reaffirmed by Needham & Company LLC.

Veracyte Stock Up 7.3%

Shares of NASDAQ:VCYT opened at $25.92 on Tuesday. Veracyte, Inc. has a 12-month low of $21.91 and a 12-month high of $60.91. The stock has a market cap of $2.08 billion, a PE ratio of 16.72 and a beta of 1.98. The business has a 50 day moving average of $43.72 and a 200-day moving average of $42.78.

Veracyte (NASDAQ:VCYT) last posted its earnings results on Wednesday, November 4th. The biotechnology company reported $0.51 EPS for the quarter, beating the consensus estimate of $0.41 by $0.10. The company had revenue of $151.75 million for the quarter, compared to the consensus estimate of $147.13 million. Veracyte had a return on equity of 9.13% and a net margin of 21.80%. The firm’s revenue for the quarter was up 15.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.51 earnings per share. Equities research analysts expect that Veracyte, Inc. will post 1.32 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Muna Bhanji sold 1,864 shares of the business’s stock in a transaction on Monday, October 19th. The stock was sold at an average price of $43.70, for a total value of $81,456.80. Following the completion of the sale, the director directly owned 40,854 shares in the company, valued at $1,785,319.80. The trade was a 4.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Karin Eastham sold 14,850 shares of the company’s stock in a transaction on Tuesday, October 27th. The shares were sold at an average price of $50.00, for a total value of $742,500.00. Following the completion of the transaction, the director directly owned 10,247 shares in the company, valued at approximately $512,350. This represents a 59.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 62,609 shares of company stock worth $2,858,904 over the last three months. 1.60% of the stock is currently owned by corporate insiders.

Veracyte, Inc is a genomic diagnostics company that develops tests to help clinicians diagnose disease and guide treatment decisions, with a focus on cancer and other complex conditions. Its tests analyze biological samples to provide information that can help distinguish between conditions and assess disease risk.

The company’s portfolio includes Afirma for thyroid nodule assessment, Decipher for prostate cancer, Prosigna for breast cancer, and Percepta for lung cancer. Veracyte also offers Envisia, a genomic test that supports the diagnosis of idiopathic pulmonary fibrosis and other forms of interstitial lung disease.

Founded in 2008 and headquartered in South San Francisco, California, Veracyte serves clinicians and patients in the United States and makes certain products available in international markets.